Schwartz Janice B, Kane Lynn, Bikle Daniel
Jewish Home of San Francisco, San Francisco, California.
Department of Medicine, University of California at San Francisco, San Francisco, California.
J Am Geriatr Soc. 2016 Jan;64(1):65-72. doi: 10.1111/jgs.13774.
To determine the dose-response relationship between 25-hydroxyvitamin D (25(OH)D) and supplemental vitamin D3 in elderly nursing home residents.
Randomized double-blind investigation.
Nursing home.
Of 81 women (n=51) and men (n=30) (mean age 87.4±8) enrolled, 72 completed the study.
Sixteen weeks of oral vitamin D3 at 800, 2,000, or 4,000 IU/d or 50,000 IU/wk.
The main outcome was 25(OH)D concentrations (tandem mass spectrometry) after 16 weeks. Free 25(OH)D and intact parathyroid hormone (iPTH) were also analyzed. Safety monitoring of calcium and estimated glomerular filtration rate was performed, and adherence and clinical status were measured.
25(OH)D concentrations increased with dose (P<.001) and were higher with 50,000 IU/wk (P<.001) than other doses and with 4,000 IU/d than 800 or 2,000 IU/d, but 800 IU and 2,000 IU/d did not differ. One subject receiving 800 IU/d had concentrations less than 20 ng/mL. All subjects receiving more than 2000 IU/d had concentrations of 20 ng/mL and greater. Free 25(OH)D concentrations rose with total 25(OH) vitamin D. Total and free 25(OH)D were related to calcium concentrations; only free 25(OH)D was related to iPTH.
25(OH)D increased linearly with 800 to 4,000 IU/d and 50,000 IU/wk of vitamin D3, without a ceiling effect. Data suggest that some elderly adults will require more than 800 IU/d of vitamin D3 to ensure adequate vitamin D levels. Changes in 25(OH)D with vitamin D3 were related to starting concentrations (greatest with the lowest concentrations and unchanged with 800 and 2,000 IU/d if 20-40 ng/mL). Relationships between serum calcium and iPTH and free 25(OH)D suggest the potential for free 25(OH)D in defining optimal 25(OH)D concentrations.
确定老年疗养院居民中25-羟基维生素D(25(OH)D)与补充维生素D3之间的剂量反应关系。
随机双盲研究。
疗养院。
81名女性(n = 51)和男性(n = 30)(平均年龄87.4±8岁)入选,72人完成研究。
口服维生素D3 16周,剂量分别为800、2000或4000 IU/天或50000 IU/周。
主要结局为16周后的25(OH)D浓度(串联质谱法)。还分析了游离25(OH)D和完整甲状旁腺激素(iPTH)。对钙和估计肾小球滤过率进行安全监测,并测量依从性和临床状态。
25(OH)D浓度随剂量增加(P<0.001),50000 IU/周组高于其他剂量组(P<0.001),4000 IU/天组高于800或2000 IU/天组,但800 IU和2000 IU/天组无差异。一名接受800 IU/天的受试者浓度低于20 ng/mL。所有接受超过2000 IU/天的受试者浓度均≥20 ng/mL。游离25(OH)D浓度随总25(OH)维生素D升高。总25(OH)D和游离25(OH)D与钙浓度有关;仅游离25(OH)D与iPTH有关。
25(OH)D随维生素D3剂量从800至4000 IU/天和50000 IU/周呈线性增加,无上限效应。数据表明,一些老年人需要超过800 IU/天的维生素D3以确保足够的维生素D水平。25(OH)D随维生素D3的变化与起始浓度有关(起始浓度最低时变化最大,若为20 - 40 ng/mL,800和2000 IU/天组无变化)。血清钙和iPTH与游离25(OH)D之间的关系表明游离25(OH)D在确定最佳25(OH)D浓度方面具有潜力。